Tuberculosis: Current therapeutics;La tuberculose: Actualités thérapeutiques

Presse Medicale

Volumn 25, Issue 39, 1996, Pages 1909-1915

  Tattevin, P ^a   Cremieux A C ^a   Bouvet, E ^a   Carbon, C ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AIDS RELATED COMPLEX; CHILD; FEMALE; FRANCE; HUMAN; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; TUBERCULOSIS; DRUG EFFICACY; DRUG TOXICITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; PATIENT COMPLIANCE; URBANIZATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CHILD; FEMALE; FRANCE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETYLSALICYLIC ACID; AMIKACIN; BCG VACCINE; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFATER; STREPTOMYCIN;

EID: 0030443484     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Cohn D, Catlin B, Peterson K et al. A 62 dose, 6-month therapy for pulmonary and extra-pulmonary tuberculosis. Ann Intern Med 1990; 112:407-15.
2. Berlie C, Bouvet E, Delepierre F et al. Diagnostic et traitement de la tuberculose. Guide d'usage des patients. Groupe d'Etude Tuberculose, Direction Générale de la Santé. Juillet 1994 (sous presse).
3. Conférence d'experts sur la tuberculose : la tuberculose en France : comment arrêter l'épidémie actuelle ? Med Mal Infect 1995; 25(suppl.):3-8.
4. Honk Kong Chest Service/Tuberculosis Research Centre, Maras. British Medical Research Council. A controlled trial of 2 months, 3 months and 12 months regimens of chemotherapy for sputum - smear - negative pulmonary tuberculosis: results at 60 months. Am Rev Respir Dis 1984; 130:23-8.
5. British Thoracic Society. A controlled trial of 6 months chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest 1984; 78:330-6.
6. Barnes P, Barrows S, Tuberculosis in the 1990s. Ann Intern Med 1993; 119:400-10.
7. Acocella G, Conti R. Interaction of RMP with other drugs. Tubercle 1980; 61:171-7.
8. Weis S, Slogum P, Blais F et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179-84.
9. Schwœbel V, Hubert B, Desenclos JC. Investigations à conduire autour d'un cas de tuberculose ou de primo-infection tuberculeuse récente. 1994; 9:39-43.
10. Barnes P, Bloch A, Davidson P et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324:1644-50.
11. Iseman M. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784-91.
12. Goble M, Iseman M, Madsen L et al. Treatment of 171 patients with pulmonary tuberculosis resistant to INH and RMP. N Engl J Med 1993; 328:527-32.
13. Telzak E, Sepkowitz K, Alpert P et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333:907-11.
14. Heifets LB, Lindholm-Levy PJ. Bacteriostatic and bactericidal activity of Ciprofloxacine and Ofloxacine against Mycobacterium Tuberculosis and Mycobacterium avium complex. Tubercle 1987; 68:267-76.
15. Lalande V, Truffot-Pernot C, Paccaly-Moulin A et al. Powerful bactericidal activity of Sparfloxacine (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother 1993; 37:2344-7.
16. Initial Therapy for Tuberculosis in the Era of Multidrug Resistance. Recommandations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993; 42 (RR-7):1-7.
17. Iseman M, Madsen L, Goble M. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141:623-5.
18. Small P, Schecter G, Goodman P et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. 1991; 324:289-94.
19. Bouvet E. Les tuberculoses multirésistantes. Presse Med 1996; 25:393-8.
20. Guerin B, Joly V, Vallée E et al. Influence of HIV status on the toxicity of antituberculous drugs. ICCAC 1994; 1362.
21. Dutt AK, Moers D, Stead WW. Short course chemotherapy for extra-pulmonary Tuberculosis. Nine years experience. Ann Intern Med 1986; 104:7-12.
22. McGowan J, Chesney P, Crossley K et al. Guidelines for the use of systemic glucocorticoid in the management selected infections. J Infect Dis 1992; 165:1-13.
23. Girgis N, Fand Z, Kilpatrick M et al. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J 1991; 10:179-83.
24. Strang J, Gibson D, Nunn A et al. Controlled trial of prednisone as adjuvant treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987; ii:1418-22.
25. American Thoracic Society. Treatment of tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359-74.
26. Lee C, Wang W, Lan R et al. Corticosteroids in the treatment of tuberculous pleuritis. A double-blind, placebo-controlled, randomized study. Chest 1988; 94:1256-9.
27. Dautzenberg B, Grosset J. Tuberculose et grossesse. Rev Mal Respir 1988; 5:279-84.
28. Grosset J. Present status of chemotherapy for tuberculosis. Rev Infect Dis 1989; 2:S347-52.
29. Snider D, Caras G, Koplan J et al. Preventive therapy with INH. Cost effectiveness of different durations of therapy. JAMA 1986; 255:1579-83.
30. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis 1992; 146:1623-33.
31. Davidson P, Quoc Le H. Drug treatment of tuberculosis. Drugs 1992; 43:651-73.